Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women

40Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

Background: Abnormal activation of PI3K/AKT/mTOR (PAM) pathway, caused by PIK3CA mutation, KRAS mutation, PTEN loss, or AKT1 mutation, is one of the most frequent signaling abnormalities in breast carcinoma. However, distribution and frequencies of mutations in PAM pathway are unclear in breast cancer patients from the mainland of China and the correlation between these mutations and breast cancer outcome remains to be identified. Methods: A total of 288 patients with invasive ductal breast cancer were recruited in this study. Mutations in PIK3CA (exons 4, 9 and 20), KRAS (exon 2) and AKT1 (exon 3) were detected using Sanger sequencing. PTEN loss was measured by immunohistochemistry assay. Correlations between these genetic aberrations and clinicopathological features were analyzed. Results: The frequencies of PIK3CA mutation, KRAS mutation, AKT1 mutation and PTEN loss were 15.6%, 1.8%, 4.4% and 35.3%, respectively. However, except for PTEN loss, which was tied to estrogen receptor (ER) status, these alterations were not associated with other clinicopathological features. Survival analysis demonstrated that PIK3CA mutation, PTEN loss and PAM pathway activation were not associated with disease-free survival (DFS). Subgroup analysis of patients with ER positive tumors revealed that PIK3CA mutation more strongly reduced DFS compared to wild-type PIK3CA (76.2% vs. 54.2%; P = 0.011). PIK3CA mutation was also an independent factor for bad prognosis in ER positive patients. Conclusions: AKT1, KRAS and PIK3CA mutations and PTEN loss all exist in women with breast cancer in the mainland China. PIK3CA mutation may contribute to the poor outcome of ER positive breast carcinomas, providing evidence for the combination of PI3K/AKT/mTOR inhibitors and endocrine therapy.

References Powered by Scopus

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

3137Citations
N/AReaders
Get full text

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

2496Citations
N/AReaders
Get full text

Targeting the phosphoinositide 3-kinase pathway in cancer

2365Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy of articular chondrocytes and attenuates inflammatory response in rats with osteoarthritis

350Citations
N/AReaders
Get full text

PIK3CA gene mutations in solid malignancies: Association with clinicopathological parameters and prognosis

66Citations
N/AReaders
Get full text

HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling

57Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Deng, L., Chen, J., Zhong, X. R., Luo, T., Wang, Y. P., Huang, H. F., … Zheng, H. (2015). Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women. PLoS ONE, 10(3). https://doi.org/10.1371/journal.pone.0120511

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

64%

Researcher 5

20%

Professor / Associate Prof. 2

8%

Lecturer / Post doc 2

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

46%

Biochemistry, Genetics and Molecular Bi... 9

35%

Nursing and Health Professions 3

12%

Agricultural and Biological Sciences 2

8%

Save time finding and organizing research with Mendeley

Sign up for free